Abstract 1617P
Background
During tyrosine kinase inhibitors (TKIs) therapy for oncogene addicted aNSCLC, impaired nutritional status reduces survival and correlates with severe drug-related toxicities. CT-scan, routinely used in oncology follow-up, is also emerging as a valuable tool for assessing body composition. NC is considered as the first clinical intervention employing to prevent the onset of malnutrition in patients (pts) with lung cancer, including the oncogene addicted-NSCLC subgroup. In the present study, we explored the impact of 1-year NC on radiological parameters in aNSCLC oncogene addicted pts treating with TKIs.
Methods
Oncogene addicted aNSCLC pts (EGFR mutated or OTHER, including ALK, ROS1, BRAF) underwent to NC+TKIs (G1) vs TKIs alone (G2). CT-scan parameters included: Muscle Area (MA, cm2) at L3 level and Total Adipose Tissue (TFAT, cm2; sum of subcutaneous, visceral and muscle adipose tissue). Body Mass Index (BMI) was also calculated. Clinical and radiological data were collected at baseline (T0) and T3, T6, T12. The Analysis of variance (ANOVA) test was performed to test differences within and between groups.
Results
A total of 69 pts were analyzed, 39 pts in G1 and 30 in G2. No substantial modifications in MA were evident in both groups throughout the entire observation period. Median MAs (cm2) were 100.7, 102.6, 103.8, 102.2 in G1 and 125.3, 132.5, 135.1, 131.7 in G2 at T0, T3, T6, and T12, respectively (ANOVA p=ns). As far as TFAT (cm2) was concerned, G1 recorded an initial decrease at T3 and a subsequent slight increase at T6 and T12 (253.0, 243.0, 263.9, 267.4), whereas a substantial incremental pattern was evident in G2 (289.4, 308.0, 345.2, 330.1) (ANOVA p=0.02). Finally, median BMIs decreased in G1 (22.5, 22.9, 22.1, 22.0) and increased in G2 (24.0, 25.0, 24.9, 24.6) (ANOVA p<0.001).
Conclusions
In patients who received NC we observed a significant reduction of TFAT and BMI whereas these parameters were increased in control patients. Thus, NC could be explored as a valid tool to avoid the occurrence of impaired conditions such as sarcopenic obesity in this patient subset.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Capelletto: Financial Interests, Advisory Board: Boehringer Ingelheim, AstraZeneca, MSD. M.L. Reale: Financial Interests, Speaker’s Bureau: Boehringer Ingelheim. S. Novello: Financial Interests, Speaker’s Bureau: Boehringer Ingelheim, AstraZeneca. M. Tampellini: Financial Interests, Speaker’s Bureau: Amgen, Servier. All other authors have declared no conflicts of interest.